Nkarta Inc (NKTX) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of Nkarta Inc stock $2.66, price $1.73, upside +53.8%, quality 37 out of 100. Rating: strongly undervalued. Calculated from audited financials with one of our 26 valuation models and 37 quality factors, updated daily.
Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment.
Show moreShow less
Its lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen, which is in Phase 1 clinical trial for the treatment of lupus nephritis; systemic sclerosis; idiopathic inflammatory myopathy; and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, as well as for systemic lupus erythematosus and myasthenia gravis.
The company has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.
Stock analysis
Nkarta Inc (NKTX) currently trades at $1.73, while our model-based Fair Value estimate is $2.66, implying the stock looks roughly 35% undervalued today.
Show more
Valuation
How firm this estimate is: it rests on 1 models at a data quality of 96/100, which puts the data coverage at low.
Scenario range: $1.76 (bear) to $3.33 (bull), the price of $1.73 sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 37/100 (below-average quality), in the Healthcare sector.
Weak Growth: Revenue growth is weak, negative or inconsistent.
Nkarta Inc reported revenue of $0 in FY2025 versus $0 in FY2021. Reported net income was −$104M in FY2025.
Key figures
Market cap $129M Micro · EPS (TTM) $−1.73 · Return on equity −46.6% · Return on assets (EBIT) −29.4% (5-year average) · Revenue (TTM) $385 · Free cash flow −$89.9M · Net debt $36.8M.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 5 out of 100 (low confidence).
What moves the price
The share trades about 53% below its 52-week high and 14% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at 54%, NKTX screens cheaper than that median.
Fair Value models
Bear$1.76Fair Value $2.66Bull$3.33
Price $1.73 · Upside +53.8%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
In the last 6 months, one officer or director sold shares worth $4,813 and none bought.
SalePaul J HastingsChief Executive Officer, Director2× since Jan 15, 2026: 27,822 shares, avg. $2.11$58,728Jun 18, 2026
SaleNadir MahmoodPresident5,649 shares at $2.07$11,693Jan 15, 2026
Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.0/100
Revenue growth is weak, negative or inconsistent.
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 558 stocks
Beats the industry median on 4/6 measures
Overall it ranks above its industry peers.
Valuation
Quality Score37 · Below median
Fair Value upside+53.8% · Top 25%
Profitability
Return on assets−25.8% · Below median
Operating margin (12 months)0.0% · Above median
Growth and dividend
Revenue growth (quarter YoY)0.0% · Above median
Valuation Multiplesvs Biotechnology median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Nkarta Inc Fair Value". https://www.fairvalue-calculator.com/stock/NKTX
Frequently asked questions
Is Nkarta Inc (NKTX) overvalued or undervalued?
As of Nov 8, 2026, our model estimates a fair value of $2.66 versus a price of $1.73, about +54% upside (undervalued).
What is the fair value of NKTX?
Our model-based fair value for Nkarta Inc is $2.66 (as of Nov 8, 2026), built from audited fundamentals. The current price: $1.73.
What is the quality score of NKTX?
Nkarta Inc has a Quality Score of 37/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Nkarta Inc (NKTX)?
Our model-based price target is the fair value of $2.66 (as of Nov 8, 2026) from 1 valuation models. Cautious scenario $1.76, optimistic scenario $3.33. It is a calculation from audited fundamentals, not an analyst target.
What is the Nkarta Inc stock forecast for 2026?
Our models put fair value at $2.66, about +54% upside versus a price of $1.73 (undervalued). Cautious scenario $1.76, optimistic scenario $3.33. The calculation is refreshed regularly with new filings.
What is the revenue of Nkarta Inc (NKTX)?
Nkarta Inc reported trailing-twelve-month revenue of about $385 (latest available figure, as of Nov 8, 2026).
What is the intrinsic value of Nkarta Inc (NKTX)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Nkarta Inc it is $2.66 per share (as of Nov 8, 2026), against a price of $1.73. It is the blended result of 1 valuation models in 1 family (Asset-Based).
Is Nkarta Inc stock overvalued or undervalued in 2026?
As of Nov 8, 2026, NKTX trades below its calculated fair value: price $1.73, fair value $2.66, a gap of about +54% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of NKTX?
No. The price is what the market pays today ($1.73); the fair value is what the company's own numbers justify ($2.66). For Nkarta Inc the two are $0.9300 per share apart. That gap is exactly why we show both numbers side by side.
How much is Nkarta Inc worth?
The market values Nkarta Inc at about $129M (market capitalisation, as of Nov 8, 2026). Per share that is $1.73; our models calculate a fair value of $2.66 per share.
What do the bullish and bearish scenarios say about NKTX?
Our models span a range for Nkarta Inc: cautious scenario $1.76, base $2.66, optimistic $3.33 per share (as of Nov 8, 2026, price $1.73). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Nkarta Inc (NKTX)?
Balance-sheet figures for Nkarta Inc (as of Nov 8, 2026): return on equity −46.6%. They feed the Quality Score of 37/100, which measures business quality independently of the share price.
How far is NKTX from its 52-week high?
Nkarta Inc trades at $1.73, about 53% below its 52-week high of $3.67 and 14% above the low of $1.52 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of $2.66 is for.
Which stocks are comparable to Nkarta Inc?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, CSL Limited, argenx SE, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Nkarta Inc stock attractive at the current price?
The data as of Nov 8, 2026: price $1.73, calculated fair value $2.66 (+54%), Quality Score 37/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of NKTX calculated?
We run Nkarta Inc through 1 models from 1 family: Asset-Based. Every model gets the same audited fundamentals; the fair value of $2.66 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Nkarta Inc currently trades 35% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Nkarta Inc (NKTX)?
The closing price on Nov 6, 2026 was $1.73. Our model-based fair value is $2.66, about +54% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Nkarta Inc right now?
The large discount to fair value meets weak quality (37/100). That raises the risk this is a value trap rather than a bargain. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range ($1.76 to $3.33) leaves room in how you read the outcome.
Key figures of Nkarta Inc
How large is the market capitalisation of Nkarta Inc (NKTX)?
The market capitalisation of Nkarta Inc is $129M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of Nkarta Inc (NKTX)?
Earnings per share at Nkarta Inc are $−1.73. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Nkarta Inc (NKTX)?
The return on equity (ROE) of Nkarta Inc is −46.6% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Nkarta Inc (NKTX)?
On an EBIT basis the return on assets of Nkarta Inc is −29.4% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
How much free cash flow does Nkarta Inc (NKTX) generate?
The free cash flow of Nkarta Inc is −$89.9M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Nkarta Inc (NKTX) carry?
The net debt of Nkarta Inc is $36.8M (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Nkarta Inc in the live analysis
One click puts Nkarta Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Thin data
Nov 8, 2026
